Managing patients with hematological malignancies during COVID-19 pandemic

Expert Rev Hematol. 2020 Aug;13(8):787-793. doi: 10.1080/17474086.2020.1787147. Epub 2020 Jul 12.

Authors

Kamal Kant Sahu¹, Jan Cerny²

Affiliations

¹ Division of Hematology and Oncology, Department of Internal Medicine, Saint Vincent Hospital , Worcester, MA, USA.
² Division of Hematology and Oncology, Department of Medicine, UMass Memorial Health Care, University of Massachusetts Medical School , Worcester, MA, USA.

PMID: 32580592
DOI: 10.1080/17474086.2020.1787147

No abstract available

Keywords: COVID-19; cancer; hematology; pandemic.

Publication types

Editorial

MeSH terms

Betacoronavirus / isolation & purification
COVID-19
Coronavirus Infections / complications
Coronavirus Infections / epidemiology
Coronavirus Infections / pathology*
Coronavirus Infections / virology
Hematologic Neoplasms / complications
Hematologic Neoplasms / mortality
Hematologic Neoplasms / pathology
Hematologic Neoplasms / therapy*
Hematopoietic Stem Cell Transplantation
Humans
Leukemia / mortality
Leukemia / pathology
Leukemia / therapy
Pandemics
Pneumonia, Viral / complications
Pneumonia, Viral / epidemiology
Pneumonia, Viral / pathology*
Pneumonia, Viral / virology
Risk Factors
SARS-CoV-2
Severity of Illness Index
Survival Rate